PSL Glass Filter Dryer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

PSL Glass Filter Dryer

The GFD® is changing the filtration and drying process in laboratories worldwide. In 2010, the GFD technology was launched combining filtration, cake washing and drying all in one glass vessel.

Working as a miniature agitated nustche filter dryer, this technology allows laboratory development simulating the manufacturing process at a small scale. When the filtration and drying process is validated during R&D, direct scale up is possible first through the three different sizes of GFD then with industrial metallic vessel during pilot plant and commercial production.

In little more than the 3 years since launch over many companies have already adopted this technology worldwide. Applications range from API filtration, peptides washing and drying, simulation for future industrial application, filtration and drying of different deposits sensitive to air or moisture, and most recently microsphere filtration.

Microspheres are small spherical particles, having a required size range. These particles can be manufactured from various natural and synthetic materials such as polymer microspheres. Suspended microspheres obtained from various micro encapsulation processes require being washed, collected by filtration then dried under appropriate conditions to give the final free flowing injectable product. After the process development phase performed with a GFD, direct scale-up is available with PSL Microsphere Refiner product range.

Website: www.powdersystems.com
E-mail: saleseu@powdersystems.com
T: +44 (0)151 448 7700
Stand location: Hall 4.1 Stand J50

LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
28%
Oversee medical treatment of patients in the US.
9%
Provide treatment for patients globally.
9%
All of the above.
41%
No government involvement in patient treatment or drug development.
13%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
From Generics to Supergenerics
CMOs and the Track-and-Trace Race: Are You Engaged Yet?
FindPharma Custom Search

Click here